Influenza Hemagglutinin Antibody Levels in the Elderly: Impact of Sex, Age, and Influenza/COVID-19 Vaccination Status During the 2021/2022 Epidemic Season in Warsaw, Poland

Overview

Journal Med Sci Monit

Specialties General Medicine
Pathology

Date 2024 Sep 17

PMID 39285625

Authors

Magdalena Proniewska-Sadowska

Anna Poznanska

Lidia Bernadeta Brydak

Affiliations

Soon will be listed here.

Abstract

BACKGROUND The purpose of the study was to determine the level of antihemagglutinin antibodies in the serum of patients in the geriatric population in Doctor's Surgery NZOZ Nucleus Warsaw, Poland, during the epidemic season 2021/2022 using the hemagglutination inhibition assay (HAI), according to anti-influenza and anti-COVID-19 vaccination, age, and sex. MATERIAL AND METHODS Serum samples taken from 256 patients aged 65 to 99 years were examined for anti-hemagglutinin antibodies and protective levels of antibodies against antigens: A/Victoria/2570/2019 (H1N1)pdm09, A/Cambodia/e0826360/2020(H3N2), B/Washington/02/2019 (B/Victoria lineage), and B/Phuket/3073/2013 (B/Yamagata lineage) of the quadrivalent influenza vaccine for epidemic season 2021/2022. RESULTS The highest protective level, ie, the percentage of people with antibody titers ≥40 was 87.5% and was recorded for subtype A/Cambodia/e0826360/2020(H3N2), the dominant type causing infections in the epidemic season 2021/2022 confirmed by molecular biology methods. Geometric mean titer (GMT) values and protective levels for B/Washington/02/2019 (B/Victoria lineage) antigen were higher for men than women (respectively 38.4 vs 67.6; P<0.001 and 58.0% vs 74.6%; P<0.001). The protective levels of antibodies among patients vaccinated vs unvaccinated against COVID-19 were higher for B/Washington/02/2019 (B/Victoria lineage) and B/Phuket/3073/2013 (B/Yamagata lineage) antigens (64.2% vs 44.4%; P=0.023 and 78.6% vs 55.6%; P=0.004). GMT values for vaccinated against COVID-19 were also higher. There were no significant differences between younger (65-79 years) and older (≥80 years) seniors. CONCLUSIONS The analysis shows differences in the level of individual antibodies, GMT and the protective level depending on subtypes of influenza A or B virus, B/Victoria or B/Yamagata lineage, sex, and previous vaccination history against influenza and COVID-19.

References

Grohskopf L, Alyanak E, Ferdinands J, Broder K, Blanton L, Talbot H . Prevention and Control of Seasonal Influenza with Vaccines: Recommendations of the Advisory Committee on Immunization Practices, United States, 2021-22 Influenza Season. MMWR Recomm Rep. 2021; 70(5):1-28. PMC: 8407757. DOI: 10.15585/mmwr.rr7005a1. View

Makam P, Matsa R . "Big Three" Infectious Diseases: Tuberculosis, Malaria and HIV/AIDS. Curr Top Med Chem. 2021; 21(31):2779-2799. DOI: 10.2174/1568026621666210916170417. View

Pedersen J . Hemagglutination-inhibition assay for influenza virus subtype identification and the detection and quantitation of serum antibodies to influenza virus. Methods Mol Biol. 2014; 1161:11-25. DOI: 10.1007/978-1-4939-0758-8_2. View

Jones-Gray E, Robinson E, Kucharski A, Fox A, Sullivan S . Does repeated influenza vaccination attenuate effectiveness? A systematic review and meta-analysis. Lancet Respir Med. 2022; 11(1):27-44. PMC: 9780123. DOI: 10.1016/S2213-2600(22)00266-1. View

Lee J, Lam G, Kevin Yin J, Loiacono M, Samson S . High-dose influenza vaccine in older adults by age and seasonal characteristics: Systematic review and meta-analysis update. Vaccine X. 2023; 14:100327. PMC: 10276206. DOI: 10.1016/j.jvacx.2023.100327. View

Kondratiuk K, Hallmann E, Szymanski K, Luniewska K, Poznanska A, Brydak L . Prevalence of circulating antibodies against hemagglutinin of influenza viruses in epidemic season 2021/2022 in Poland. Acta Biochim Pol. 2024; 71:12289. PMC: 11077356. DOI: 10.3389/abp.2024.12289. View

Marin-Hernandez D, Schwartz R, Nixon D . Epidemiological evidence for association between higher influenza vaccine uptake in the elderly and lower COVID-19 deaths in Italy. J Med Virol. 2020; 93(1):64-65. PMC: 7300995. DOI: 10.1002/jmv.26120. View

Yang J, Huang X, Zhang J, Fan R, Zhao W, Han T . Sex-specific differences of humoral immunity and transcriptome diversification in older adults vaccinated with inactivated quadrivalent influenza vaccines. Aging (Albany NY). 2021; 13(7):9801-9819. PMC: 8064175. DOI: 10.18632/aging.202733. View

Dong E, Ratcliff J, Goyea T, Katz A, Lau R, Ng T . The Johns Hopkins University Center for Systems Science and Engineering COVID-19 Dashboard: data collection process, challenges faced, and lessons learned. Lancet Infect Dis. 2022; 22(12):e370-e376. PMC: 9432867. DOI: 10.1016/S1473-3099(22)00434-0. View

10.

Brydak L, Szymanski K, Kondratiuk K, Poznanska A, Kolondra A, Hallmann E . Importance of Influenza Anti-Hemagglutinin Antibodies During the SARS-CoV-2 Pandemic in the 2019/2020 Epidemic Season in Poland. Med Sci Monit. 2022; 28:e936495. PMC: 9128455. DOI: 10.12659/MSM.936495. View

11.

Reber A, Katz J . Immunological assessment of influenza vaccines and immune correlates of protection. Expert Rev Vaccines. 2013; 12(5):519-36. PMC: 9002926. DOI: 10.1586/erv.13.35. View

12.

Veronese N, Smith L, Di Gennaro F, Bruyere O, Yang L, Demurtas J . Influenza Vaccination and COVID-19 Outcomes in People Older than 50 Years: Data from the Observational Longitudinal SHARE Study. Vaccines (Basel). 2022; 10(6). PMC: 9229857. DOI: 10.3390/vaccines10060899. View